{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:17:25Z","timestamp":1780438645322,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this phase II study was to evaluate the feasibility of hypofractionated radiotherapy (HFRT) with a dose of 36.5\u2009Gy in 10 fractions in postmastectomy patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From March 2014 to December 2015, 85 patients with locally advanced breast cancer were eligible to participate in this study with a schedule of 36.5\u2009Gy in 10 fractions. Intensity-modulated radiation therapy (IMRT) was delivered to the chest wall with or without the supraclavicular region. The primary endpoint was radiation-related toxicities. The secondary endpoints were locoregional failure-free survival (LRFFS), disease-free survival (DFS) and overall survival (OS). And the outcomes were compared with our retrospective study of 72 patients with 42.5\u2009Gy in 16 fractions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up was 69.0 (range 66.5-71.5) months in the 36.5\u2009Gy group and 93.0 (range 91.9-94.1) months in the 42.5\u2009Gy group, respectively. Radiation-related toxicities were mainly grade 1, although a few patients had grade 2 plexopathy (1.2%) and acute skin toxicity (1.2%) in the 36.5\u2009Gy group, and grade 2 acute skin toxicity (5.6%) and lymphedema (4.2%) in the 42.5\u2009Gy group. There were no significant differences between the groups in acute and late toxicities. For all the patients, the 5-year LRFFS, DFS and OS were 97.7 and 100.0%, 93.1 and 90.3%, 98.8 and 97.2%, respectively, without significant differences between the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Postmastectomy HFRT with a schedule of 36.5\u2009Gy in 10 fractions was feasible, with mild toxicities and excellent 5-year clinical outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Trial registration number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=5179\">ChiCTR-ONRC-14004391<\/jats:ext-link>.<\/jats:p>\n                <jats:p>Date of registration: 9\/3\/2014.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09032-8","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:01:27Z","timestamp":1638342087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions"],"prefix":"10.1186","volume":"21","author":[{"given":"Huayong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangkun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"9032_CR1","unstructured":"International Agency for Research on Cancer (IARC). Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Available from: https:\/\/www.iarc.who.int\/fr\/news-events. Accessed 25 Feb 2021."},{"key":"9032_CR2","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087\u2013106. https:\/\/doi.org\/10.1016\/S0140-6736(05)67887-7.","journal-title":"Lancet"},{"key":"9032_CR3","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1200\/JCO.2005.02.8738","volume":"24","author":"HM Nielsen","year":"2006","unstructured":"Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish breast cancer cooperative group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268\u201375. https:\/\/doi.org\/10.1200\/JCO.2005.02.8738.","journal-title":"J Clin Oncol"},{"key":"9032_CR4","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2014","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(14)60488-8.","journal-title":"Lancet"},{"key":"9032_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0906260.","journal-title":"N Engl J Med"},{"key":"9032_CR6","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.20.01363","volume":"38","author":"BV Offersen","year":"2020","unstructured":"Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38:3615\u201325. https:\/\/doi.org\/10.1200\/JCO.20.01363.","journal-title":"J Clin Oncol"},{"key":"9032_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(13)70386-3.","journal-title":"Lancet Oncol"},{"key":"9032_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","volume":"20","author":"SL Wang","year":"2019","unstructured":"Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20:352\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(18)30813-1.","journal-title":"Lancet Oncol"},{"key":"9032_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.2016.70.7158","volume":"35","author":"AJ Khan","year":"2017","unstructured":"Khan AJ, Poppe MM, Goyal S, et al. Hypofractionated postmastectomy radiation therapy is safe and effective: first results from a prospective phase II trial. J Clin Oncol. 2017;35:2037\u201343. https:\/\/doi.org\/10.1200\/JCO.2016.70.7158.","journal-title":"J Clin Oncol"},{"key":"9032_CR10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0360-3016(90)90216-7","volume":"19","author":"F Baillet","year":"1990","unstructured":"Baillet F, Housset M, Maylin C, et al. The use of a specific hypofractionated radiation therapy regimen versus classical fractionation in the treatment of breast cancer: a randomized study of 230 patients. Int J Radiat Oncol Biol Phys. 1990;19:1131\u20133. https:\/\/doi.org\/10.1016\/0360-3016(90)90216-7.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR11","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.5271\/sjweh.3960","volume":"395","author":"A Murray Brunt","year":"2020","unstructured":"Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613\u201326. https:\/\/doi.org\/10.5271\/sjweh.3960.","journal-title":"Lancet"},{"key":"9032_CR12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ijrobp.2004.05.072","volume":"60","author":"BS Rosenstein","year":"2004","unstructured":"Rosenstein BS, Lymberis SC, Formenti SC. Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys. 2004;60:1393\u2013404. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.05.072.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0167-8140(90)90149-q","volume":"19","author":"HD Thames","year":"1990","unstructured":"Thames HD, Bentzen SM, Turesson I, et al. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19:219\u201335. https:\/\/doi.org\/10.1016\/0167-8140(90)90149-q.","journal-title":"Radiother Oncol"},{"key":"9032_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0167-8140(89)90084-4","volume":"15","author":"RG Dale","year":"1989","unstructured":"Dale RG. Time-dependent tumour repopulation factors in linear-quadratic equations--implications for treatment strategies. Radiother Oncol. 1989;15:371\u201381. https:\/\/doi.org\/10.1016\/0167-8140(89)90084-4.","journal-title":"Radiother Oncol"},{"key":"9032_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ijrobp.2020.03.020","volume":"107","author":"MM Poppe","year":"2020","unstructured":"Poppe MM, Yehia ZA, Baker C, et al. 5-year update of a multi-institution prospective phase 2 hypofractionated postmastectomy radiation therapy trial. Int J Radiat Oncol Biol Phys. 2020;107:694\u2013700. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.03.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000449433","volume":"11","author":"V Kouloulias","year":"2016","unstructured":"Kouloulias V, Mosa E, Zygogianni A, et al. A retrospective analysis of toxicity and efficacy for 2 hypofractionated irradiation schedules versus a conventional one for post-mastectomy adjuvant radiotherapy in breast cancer. Breast Care. 2016;11:328\u201332. https:\/\/doi.org\/10.1159\/000449433.","journal-title":"Breast Care"},{"key":"9032_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13014-019-1378-x","volume":"14","author":"I Chitapanarux","year":"2019","unstructured":"Chitapanarux I, Klunklin P, Pinitpatcharalert A, et al. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity. Radiat Oncol. 2019;14:175\u201384. https:\/\/doi.org\/10.1186\/s13014-019-1378-x.","journal-title":"Radiat Oncol"},{"key":"9032_CR18","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ijrobp.2020.07.2313","volume":"108","author":"TA Koulis","year":"2020","unstructured":"Koulis TA, Nichol AM, Truong PT, et al. Hypofractionated adjuvant radiation therapy is effective for patients with lymph node-positive breast cancer: a population-based analysis. Int J Radiat Oncol Biol Phys. 2020;108:1150\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.2313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR19","unstructured":"Radiation Therapy Oncology Group (RTOG). Breast cancer atlas for radiation therapy planning: consensus definitions. Available from: http:\/\/www.rtog.org\/LinkClick.aspx?fileticket=vzJFhPaBipE%3d&tabid=236. Accessed 10 Apr 2021."},{"key":"9032_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","volume":"114","author":"BV Offersen","year":"2015","unstructured":"Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114:3\u201310. https:\/\/doi.org\/10.1016\/j.radonc.2014.11.030.","journal-title":"Radiother Oncol"},{"key":"9032_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.radonc.2017.09.031","volume":"126","author":"JS Chang","year":"2018","unstructured":"Chang JS, Lee J, Chun M, et al. Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: a multi-institutional validation study of the ESTRO consensus guideline on clinical target volume. Radiother Oncol. 2018;126:139\u201347. https:\/\/doi.org\/10.1016\/j.radonc.2017.09.031.","journal-title":"Radiother Oncol"},{"key":"9032_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijrobp.2014.09.011","volume":"91","author":"EH Wang","year":"2015","unstructured":"Wang EH, Mougalian SS, Soulos PR, et al. Adoption of intensity modulated radiation therapy for early-stage breast cancer from 2004 through 2011. Int J Radiat Oncol Biol Phys. 2015;91:303\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.09.011.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.radonc.2006.12.008","volume":"82","author":"E Donovan","year":"2007","unstructured":"Donovan E, Bleakley N, Denholm E, Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82:254\u201364. https:\/\/doi.org\/10.1016\/j.radonc.2006.12.008.","journal-title":"Radiother Oncol"},{"key":"9032_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3857\/roj.2017.00381","volume":"36","author":"K Rastogi","year":"2018","unstructured":"Rastogi K, Sharma S, Gupta S, et al. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. Radiat Oncol J. 2018;36:71\u20138. https:\/\/doi.org\/10.3857\/roj.2017.00381.","journal-title":"Radiat Oncol J"},{"key":"9032_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ijrobp.2018.04.075","volume":"101","author":"R Jagsi","year":"2018","unstructured":"Jagsi R, Griffith KA, Moran JM, et al. A randomized comparison of radiation therapy techniques in the Management of Node-Positive Breast Cancer: primary outcomes analysis. Int J Radiat Oncol Biol Phys. 2018;101:1149\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.075.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR26","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ijrobp.2020.07.027","volume":"108","author":"JG Bazan","year":"2020","unstructured":"Bazan JG, Healy E, Beyer S, et al. Clinical effectiveness of an adaptive treatment planning algorithm for intensity modulated radiation therapy versus 3D conformal radiation therapy for node-positive breast cancer patients undergoing regional nodal irradiation\/Postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2020;108:1159\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.027.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9032_CR27","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1200\/JCO.2007.15.2488","volume":"26","author":"J-P Pignol","year":"2008","unstructured":"Pignol J-P, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085\u201392. https:\/\/doi.org\/10.1200\/JCO.2007.15.2488.","journal-title":"J Clin Oncol"},{"key":"9032_CR28","doi-asserted-by":"publisher","first-page":"80012","DOI":"10.18632\/oncotarget.20820","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Wang X, Ma J, et al. Prospective evaluation of skin toxicities in patients receiving post-mastectomy irradiation of chest wall, supra\/infraclavicular and internal mammary nodes delivered by conventional versus intensity-modulated radiotherapy technique. Oncotarget. 2017;8:80012\u20139. https:\/\/doi.org\/10.18632\/oncotarget.20820.","journal-title":"Oncotarget"},{"issue":"1086","key":"9032_CR29","doi-asserted-by":"publisher","first-page":"20160874","DOI":"10.1259\/bjr.20160874","volume":"91","author":"V Lancellotta","year":"2018","unstructured":"Lancellotta V, Iacco M, Perrucci E, et al. Comparing four radiotherapy techniques for treating the chest wall plus levels III-IV draining nodes after breast reconstruction. Br J Radiol. 2018;91(1086):20160874. https:\/\/doi.org\/10.1259\/bjr.20160874.","journal-title":"Br J Radiol"},{"key":"9032_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/07357907.2018.1545854","volume":"36","author":"V Lancellotta","year":"2018","unstructured":"Lancellotta V, Chierchini S, Perrucci E, et al. Skin toxicity after chest wall\/breast plus level III-IV lymph nodes treatment with helical tomotherapy. Cancer Investig. 2018;36:504\u201311. https:\/\/doi.org\/10.1080\/07357907.2018.1545854.","journal-title":"Cancer Investig"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09032-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:01:30Z","timestamp":1638342090000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9032"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09032-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the ethics board of the Chinese PLA General Hospital, and all eligible patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests regarding this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1284"}}